← All Protokinetix, INC filings

Protokinetix, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
PKTX
Protokinetix, INC
8-K: ProtoKinetix Appoints New President and Subsidiary Update
ProtoKinetix appoints Dr. Keith Brunt as President and Director while announcing a $253 million valuation for its ophthalmic patent portfolio.
OTC.Pink
PKTX
Protokinetix, INC
8-K: ProtoKinetix CEO Addresses Leadership Transition, Reaffirms AAGP Focus
ProtoKinetix, Incorporated announced a leadership transition following the passing of Clarence Smith, with Michael Guzzetta now serving as CEO, reaffirming the company's commitment to its AAGP molecule development.
OTC.Pink
PKTX
Protokinetix, INC
8-K/A: ProtoKinetix Names New CEO After Tragic Death
ProtoKinetix, a clinical-stage biomedical company, announced the tragic death of its President and CEO, Clarence E. Smith, and the immediate appointment of Michael Guzzetta as his successor.
OTC.Pink
PKTX
Protokinetix, INC
8-K: ProtoKinetix Mourns CEO Smith, Appoints Guzzetta Successor
ProtoKinetix, Incorporated announces the tragic death of its President and CEO, Clarence E. Smith, and the immediate appointment of Michael Guzzetta as his successor.
OTC.Pink
PKTX
Protokinetix, INC
8-K: ProtoKinetix Boosts Authorized Shares to 600M
ProtoKinetix, Incorporated stockholders approved an amendment to increase the total authorized common stock from 500 million to 600 million shares.